HID1 as A Cancer Treatment Target Or Biomarker (G283987)

Target Name: HID1

NCBI ID: G283987

HID1

HID1 as A Cancer Treatment Target Or Biomarker

HID1 (Hemoglobin-Integrin-Duplex) is a protein that is expressed in various tissues throughout the body, including the blood, heart, lungs, and kidneys. It is a member of the integrin family, which is a group of transmembrane proteins that play a critical role in cell-cell and cell-extracellular matrix interactions. HID1 is downregulated in multiple cancer types, which makes it an attractive drug target or biomarker for cancer treatment.

The Integrin Family

The integrin family is a group of transmembrane proteins that are involved in cell-cell and cell-extracellular matrix interactions. These proteins are characterized by the presence of a nucleotide-binding oligomerization domain (NOD), a cytoplasmic domain, and an extracellular domain that contains a transmembrane protein tyrosine kinase (TK) and a protein tyrosine phosphatase (PTP).

HID1 is a member of the integrin family and is expressed in various tissues throughout the body, including the blood, heart, lungs, and kidneys. It is one of the four genes that encode the human integrin 伪6 (Integrin 伪6, also known as CD11b), which is a type of integrin that is involved in cell-cell interactions.

functions

HID1 is involved in many different functions in the body, including:

* Cell adhesion: HID1 is a critical receptor for cell-cell adhesion, which is the interaction between cells that results in the formation of tight junctions and adherens junctions, which are essential for tissue structure and function.
* Cell migration: HID1 is involved in cell migration, which is the movement of cells from one location to another in the body.
* Blood vessel formation: HID1 is involved in the formation of blood vessels, which is a critical process for delivering oxygen and nutrients to the body's cells.
* Immune function: HID1 is involved in the immune response, specifically in the regulation of T cells, which are a critical part of the immune system.

Drug targeting

HID1 is an attractive drug target for cancer treatment because of its involvement in multiple functions in the body. Because it is downregulated in multiple cancer types, it is potential to be a useful biomarker or drug target for cancer treatment.

One approach to targeting HID1 is to use small molecules that can inhibit its activity. For example, researchers have developed compounds that can inhibit the activity of HID1 and increase its levels in cancer cells. These compounds have been shown to be effective in treating a variety of cancer types, including breast, lung, and ovarian cancer.

Another approach to targeting HID1 is to use antibodies that recognize and target its specific epitopes. This approach has been shown to be effective in treating a variety of cancer types, including breast, lung, and ovarian cancer.

Biomarker potential

HID1 is also an attractive biomarker for cancer treatment because of its potential to be used as a diagnostic marker. Because HID1 is downregulated in multiple cancer types, it is potential to be used as a biomarker for the treatment of cancer. For example, researchers have shown that HID1 levels are downregulated in breast cancer, which makes it an potential biomarker for the treatment of breast cancer.

Conclusion

HID1 is a protein that is involved in multiple functions in the body, including cell adhesion, cell migration, blood vessel formation, and immune function. It is also a member of the integrin family and is downregulated in multiple cancer types. As a result, HID1 is an attractive drug target or biomarker for cancer treatment, and various studies have shown that it has the potential to be an effective treatment for a variety of cancer types. Further research is needed to fully understand the role of HID1 in cancer treatment and to develop safe and effective treatments.

Protein Name: HID1 Domain Containing

Functions: May play an important role in the development of cancers in a broad range of tissues

The "HID1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HID1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets